Over the last two days, Novo Nordisk A/S (NYSE:NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
On the other hand, Eli Lilly and Co. (NYSE:LLY) investors cheered the company’s better-than-expected fourth quarter earnings and upbeat fiscal 2026 guidance.
Novo Nordisk 2026 Guidance
Novo Nordisk expects sales growth for 2026, which excludes revenue of $4.2 billion from the reversal of 340B provisions, is expected to be -5% to -13% at CER.
The company said that the sales outlook is impacted by lower realized prices, including impacts related to the “Most Favoured Nations” agreement in the U.S. and the patent expiry of the semaglutide molecule in certain international operation markets, as well as competition.
In 2025, Novo Nordisk’s sales increased by 10% to 309.06 billion Danish kroner at CER, and operating profit increased by 6% to 127.66 billion …